PB0057 - Recovery after COVID-19 and persisting Endothelial Cell Activation and Hypercoagulability- The Prospective Observational ROADMAP-Post COVID-19 Study

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

PV

Patrick Van Dreden

PhD clinical research manager
Clinical Research Department, Diagnostica Stago
Gennevilliers, Ile-de-France, France
ET

Evangelos Terpos

Professor of Hematology
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
Athens, Attiki, Greece
MP

Marianna Politou

Haematologist,Assistant Professor at University of Athens
Hematology Laboratory—Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens
Athens, Attiki, Greece
Ma

Meletios a.Dimopoulos

Professor of the Department of Clinical Therapeutics
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
Athens, Attiki, Greece
IE

Ismail Elalamy

Professor of Hematology
Thrombosis and Haemostasis Centre, Biological Hematology Department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.; Department of Obstetrics and Gynecology, I M Sechenov First Moscow State Medical University, Moscow, Russia
Paris, Ile-de-France, France

Presenting Author(s)

GG

Grigorios Gerotziafas

Professor of Hematology
Sorbonne Université, INSERM UMR_S938, Research Group « Cancer-Hemostasis-Angiogenesis », Centre de Recherche Saint-Antoine, Institut Universitaire de Cancérologie, Paris, France ; Thrombosis and Haemostasis Centre, Biological Hematology Department, Hôpital Tenon, Assistance Pu-blique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.
Paris, Ile-de-France, France

Background: Hypercoagulable state and endothelial cell activation are common alterations in patients with COVID-19. Nevertheless, the hypothesis of persistent hypercoagulability and endothelial cell activation following recovery from COVID-19 remains an unresolved issue.

Aims: To investigate the persistence of endothelial cell activation and hypercoagulability after recovery from COVID-19. Patients/Methods. COVID-19 survivors (n = 208) and 30 healthy individuals were enrolled in this study.

Methods: The following biomarkers were measured: procoagulant phospholipid-dependent clotting time (PPL-ct), D-Dimer, fibrin monomers (FM), free Tissue factor pathway inhibitor (free-TFP)I, heparinase, and soluble thrombomodulin (sTM). Antibodies against SARS-CoV-2 (IgG and IgA) were also measured

Results: The median interval between symptom onset and screening for SARS-CoV-2 antibodies was 62 days (IQR = 22 days). Survivors showed significantly higher levels of D-Dimers, FM, TFPI, and heparanase as compared to that of the control group. Survivors had significantly shorter PPL-ct. Elevated D-dimer was associated with older age. Elevated FM was associated with female gender. Elevated heparanase was independently associated with male gender. Decreased Procoag-PPL clotting time was associated with female gender. One out of four of COVID-19 survivors showed increase at least one biomarker of endothelial cell activation or hypercoagulability

Conclusion(s): Two months after onset of COVID-19, a significant activation of endothelial cells and in vivo thrombin generation persists in at least one out of four survivors of COVID-19. The clinical relevance of these biomarkers in the diagnosis and follow-up of patients with long COVID-19 merits to be evaluated in a prospective clinical study.